PHIO
Phio Pharmaceuticals Corp. [PHIO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PHIO Stock Summary
Top 10 Correlated ETFs
PHIO
Top 10 Correlated Stocks
PHIO
In the News
PHIO Financial details
Company Rating
Sell
Market Cap
3.09M
Income
-10.83M
Revenue
0
Book val./share
2.06
Cash/share
2.27
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-0.16
Forward P/E
-
PEG
0.04
P/S
-
P/B
0.26
P/C
0.28
P/FCF
-0.17
Quick Ratio
3.61
Current Ratio
4.01
Debt / Equity
0
LT Debt / Equity
-
-
-
EPS (TTM)
-6.27
EPS next Y
-
EPS next Q
-
EPS this Y
-47.74%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-53.14%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-55.26%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-121%
ROE
-131%
ROC
-1.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.5-12.27
52W High
-
52W Low
-
RSI
38
Rel Volume
0.19
Avg Volume
327.25K
Volume
61.68K
Perf Week
-8.82%
Perf Month
-31.27%
Perf Quarter
-50.94%
Perf Half Y
-54.12%
-
-
-
-
Beta
1.418
-
-
Volatility
0.01%, 0.14%
Prev Close
0%
Price
0.6378
Change
1.51%
PHIO Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.55 | 0 | 0 | 0 | 0 | |
| Net income per share | -230.23 | -23 | -12.36 | -9.95 | -5.2 | |
| Operating cash flow per share | -225.13 | -23.03 | -11.09 | -10.67 | -5.16 | |
| Free cash flow per share | -227.01 | -23.07 | -11.14 | -10.78 | -5.16 | |
| Cash per share | 180.57 | 37.26 | 22.5 | 10.37 | 4.07 | |
| Book value per share | 149.69 | 34.05 | 20.51 | 9.54 | 3.71 | |
| Tangible book value per share | 149.69 | 34.05 | 20.51 | 9.54 | 3.71 | |
| Share holders equity per share | 149.69 | 34.05 | 20.51 | 9.54 | 3.71 | |
| Interest debt per share | 13.49 | 1.68 | 0.27 | 0.11 | 0.02 | |
| Market cap | 4.33M | 12.34M | 12.83M | 5.07M | 1.58M | |
| Enterprise value | -2.08M | -1.26M | -10.93M | -6.41M | -6.87M | |
| P/E ratio | -0.49 | -1.4 | -0.97 | -0.45 | -0.15 | |
| Price to sales ratio | 206.37 | 0 | 0 | 0 | 0 | |
| POCF ratio | -0.5 | -1.4 | -1.08 | -0.42 | -0.15 | |
| PFCF ratio | -0.5 | -1.4 | -1.08 | -0.41 | -0.15 | |
| P/B Ratio | 0.75 | 0.95 | 0.59 | 0.47 | 0.2 | |
| PTB ratio | 0.75 | 0.95 | 0.59 | 0.47 | 0.2 | |
| EV to sales | -99.15 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 0.23 | 0.14 | 0.81 | 0.56 | 0.65 | |
| EV to operating cash flow | 0.24 | 0.14 | 0.92 | 0.53 | 0.64 | |
| EV to free cash flow | 0.24 | 0.14 | 0.92 | 0.52 | 0.64 | |
| Earnings yield | -2.04 | -0.71 | -1.03 | -2.23 | -6.84 | |
| Free cash flow yield | -2.01 | -0.71 | -0.93 | -2.42 | -6.79 | |
| Debt to equity | 0.09 | 0.05 | 0.01 | 0.03 | 0 | |
| Debt to assets | 0.06 | 0.04 | 0.01 | 0.02 | 0 | |
| Net debt to EBITDA | 0.71 | 1.56 | 1.76 | 1 | 0.8 | |
| Current ratio | 3.88 | 6.91 | 8.06 | 6.9 | 5.71 | |
| Interest coverage | 0 | 0 | 1.5K | 65.5 | 0 | |
| Income quality | 0.97 | 1 | 0.89 | 1.06 | 0.99 | |
| Dividend Yield | 0 | 0.33 | 0 | 0 | 0 | |
| Payout ratio | 0 | -0.46 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 224.19 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 204.76 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0.01 | 0 | |
| Capex to revenue | -3.43 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.07 | -0.26 | -0.68 | -0.63 | -0.03 | |
| Stock based compensation to revenue | 14.29 | 0 | 0 | 0 | 0 | |
| Graham number | 880.58 | 132.76 | 75.52 | 46.2 | 20.83 | |
| ROIC | -1.31 | -0.62 | -0.6 | -1 | -1.37 | |
| Return on tangible assets | -1.1 | -0.56 | -0.52 | -0.88 | -1.16 | |
| Graham Net | 120.91 | 30.14 | 19.47 | 8.63 | 3.29 | |
| Working capital | 5.42M | 12.97M | 21.66M | 10.64M | 7.69M | |
| Tangible asset value | 5.75M | 13.02M | 21.93M | 10.84M | 7.73M | |
| Net current asset value | 5.01M | 12.44M | 21.49M | 10.47M | 7.69M | |
| Invested capital | 0.09 | 0.05 | 0.01 | 0.03 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 679.5K | 768.5K | 505.5K | 531K | 718K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 68.67K | 1.45K | 537.99 | 1.47K | 1.3K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.01 | 0.25 | 0.68 | 0.25 | 0.28 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -1.54 | -0.68 | -0.6 | -1.04 | -1.4 | |
| Capex per share | -1.88 | -0.05 | -0.05 | -0.11 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -2.28 | -3.15 | -1.47 | -1.14 | -0.51 | |
| Operating cash flow per share | -2.37 | -2.37 | -1.6 | -1.19 | -0.63 | |
| Free cash flow per share | -2.47 | -2.37 | -1.61 | -1.19 | -0.63 | |
| Cash per share | 10.34 | 7.91 | 6.54 | 3.45 | 2.27 | |
| Book value per share | 9.52 | 6.4 | 5.73 | 2.96 | 2.06 | |
| Tangible book value per share | 9.52 | 6.4 | 5.73 | 2.96 | 2.06 | |
| Share holders equity per share | 9.52 | 6.4 | 5.73 | 2.96 | 2.06 | |
| Interest debt per share | 0.15 | 0.12 | 0.06 | 0.03 | 0.01 | |
| Market cap | 5.08M | 6.42M | 4.96M | 3.68M | 2.85M | |
| Enterprise value | -6.4M | -2.48M | -6.24M | -4.65M | -5.61M | |
| P/E ratio | -0.49 | -0.45 | -0.49 | -0.33 | -0.38 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -1.88 | -2.37 | -1.79 | -1.27 | -1.2 | |
| PFCF ratio | -1.8 | -2.37 | -1.79 | -1.27 | -1.2 | |
| P/B Ratio | 0.47 | 0.88 | 0.5 | 0.51 | 0.37 | |
| PTB ratio | 0.47 | 0.88 | 0.5 | 0.51 | 0.37 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | 2.34 | 0.7 | 2.5 | 1.67 | 3.24 | |
| EV to operating cash flow | 2.36 | 0.91 | 2.25 | 1.6 | 2.37 | |
| EV to free cash flow | 2.27 | 0.91 | 2.25 | 1.6 | 2.37 | |
| Earnings yield | -0.51 | -0.56 | -0.51 | -0.75 | -0.67 | |
| Free cash flow yield | -0.55 | -0.42 | -0.56 | -0.79 | -0.83 | |
| Debt to equity | 0.03 | 0.02 | 0.01 | 0.01 | 0 | |
| Debt to assets | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | 4.2 | 2.5 | 4.48 | 3 | 4.89 | |
| Current ratio | 6.9 | 3.92 | 5.03 | 4.01 | 5.71 | |
| Interest coverage | 20.07 | 0 | 0 | 0 | 0 | |
| Income quality | 0.99 | 0.75 | 1.09 | 1.04 | 1.25 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.83 | 0 | -0.11 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 22.09 | 21.31 | 13.79 | 8.7 | 4.84 | |
| ROIC | -0.23 | -0.47 | -0.25 | -0.37 | -0.23 | |
| Return on tangible assets | -0.2 | -0.37 | -0.21 | -0.29 | -0.2 | |
| Graham Net | 8.61 | 5.81 | 5.16 | 2.49 | 1.83 | |
| Working capital | 10.64M | 7.01M | 9.64M | 7M | 7.69M | |
| Tangible asset value | 10.84M | 7.31M | 9.9M | 7.21M | 7.73M | |
| Net current asset value | 10.47M | 7.01M | 9.64M | 7M | 7.69M | |
| Invested capital | 0.03 | 0.02 | 0.01 | 0.01 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 661K | 840.5K | 771.5K | 407K | 415K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.52K | 1.73K | 1.23K | 331.28 | 1.38K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.06 | 0.05 | 0.07 | 0.27 | 0.07 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.24 | -0.49 | -0.26 | -0.39 | -0.25 | |
| Capex per share | -0.1 | 0 | 0 | 0 | 0 |
PHIO Frequently Asked Questions
What is Phio Pharmaceuticals Corp. stock symbol ?
Phio Pharmaceuticals Corp. is a US stock , located in Marlborough of Ma and trading under the symbol PHIO
What is Phio Pharmaceuticals Corp. stock quote today ?
Phio Pharmaceuticals Corp. stock price is $0.6378 today.
Is Phio Pharmaceuticals Corp. stock public?
Yes, Phio Pharmaceuticals Corp. is a publicly traded company.
Company Profile
- Volume Average 327.25K
- Market Capitalization 3.09M
- Employee 8
- CEO Mr. Robert J. Bitterman
- Headquarters Marlborough,MA,US
- IPO Date 2012-05-10
-
Website
https://www.phiopharma.com 
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
